[RESEARCH BLOG] · 2026-08-25
QT Imaging Holdings (QTI) Gains Momentum on Strong Q2 Results and U.S. Commercial Expansion – BUY Signal in Recovery Regime
By Pierre Brunelle · Founder & Research Lead
Lede: QT Imaging Holdings closed at $3.31, up 13.75 % as of 2026‑08‑24 (Monday, US session). LOPJLB’s proprietary scanner flags a BUY directional signal with a top‑tier Score 5 while the broader market is classified in a RECOVERY regime.
Recent News Flow
-
QT Imaging Delivers Strong Second Quarter Growth While Building the Foundation for Commercial Scale (2026‑08‑12) – The press release announced double‑digit unit‑shipment growth of the QT Ultrasound Breast Scanner and the signing of the first multi‑site contracts with two major U.S. health systems. Management highlighted the transmission‑mode ultrasound technology as a cost‑effective alternative to MRI for breast‑cancer screening.
-
QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders (2026‑08‑18) – In a letter dated 18 August 2026, CEO Raluca Dinu outlined a $12 million investment in next‑generation acoustic‑CT hardware slated for early 2027 and a $3.1 million reduction in R&D expense YoY to preserve cash as commercial scale expands.
-
QT Imaging Advances Direct U.S. Commercial Strategy to Accelerate Adoption of its Breast Acoustic CT Scanner with Two Key Hires (2026‑08‑04) – The company announced two senior hires (a former senior director of market access and a regional sales leader) tasked with driving adoption across Midwest and Southeast hospital networks, targeting $8 million of incremental pipeline revenue within twelve months.
-
QT Imaging Announces Successful Completion of First FDA Routine Inspection with Zero Form 483 Observations (2026‑07‑07) – The FDA inspection concluded with no Form 483 findings, removing a key barrier to broader U.S. market entry.
-
QT Imaging Receives Israeli Ministry of Health Regulatory Registration (2026‑07‑28) – Full regulatory registration in Israel clears the path for sales within the public health system.
-
QT Imaging Appoints Medical Imaging and Digital Health Executive Dr. Julia Albright as Chief Science Officer (2026‑07‑29) – Strengthens the firm’s scientific leadership as it prepares for larger commercial roll‑outs.
-
QT Imaging Q2 2026 Earnings Call Transcript (2026‑08‑12) – The call confirmed that Q2 2026 revenue is estimated at $9.6 million, roughly 50 % higher than the first half of 2025, and that cash burn narrowed to $1.8 million for the quarter.
-
QT Imaging to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026 (2026‑08‑05) – Reminder of the upcoming earnings release and conference call.
-
QT Imaging Holdings Announces Results of 2026 Annual Stockholder Meeting (2026‑07‑28) – Provides governance updates and shareholder approvals relevant to the company’s growth plan.
These catalysts collectively reinforce the BUY signal generated by LOPJLB.
Fundamentals and Valuation
QT Imaging operates in the Medical‑Devices segment of the healthcare sector, focusing on advanced breast‑imaging solutions that combine reflection‑mode and transmission‑mode ultrasound. The company’s market capitalization stands at $45.6 million, a small‑cap that can amplify price movements on news flow.
Valuation Snapshot
| Metric | Value |
|---|---|
| P/E (TTM) | –2.33 |
| P/B | 21.86 |
| EV/EBITDA (TTM) | –2.59 |
| Gross Margin | 39.56 % |
| Operating Margin | –17.45 % |
| Net Margin | –65.31 % |
| Debt/Equity | 192.9 % |
The negative price‑to‑earnings and EV/EBITDA multiples indicate that QT Imaging is presently unprofitable on a GAAP basis, a common trait among early‑stage medical‑device firms that are still investing heavily in R&D and regulatory pathways. The price‑to‑book ratio of 21.86 suggests that the market is pricing the firm well above its current book value, likely reflecting expectations of future commercial scale and the strategic value of its proprietary acoustic‑CT technology.
Revenue Trajectory
| Fiscal Year | Revenue (USD) | YoY % Change |
|---|---|---|
| 2021 | $365,148 | – |
| 2022 | – (not disclosed) | – |
| 2023 | $40,355 | –89.0 % |
| 2024 | $4,878,665 | +12,000 % |
| 2025 | $18,925,000 | +288 % |
The 2024‑2025 surge reflects the shift from prototype to commercial sales. The Q2 2026 press release indicates that the upward trajectory is persisting, with unit shipments up ~15 % QoQ and first‑half revenue estimated at $9.6 million, roughly 50 % higher than the same period in 2025.
Profitability and Cash Flow
- Gross margin: 39.56 % (respectable for hardware).
- Operating margin: –17.45 %
- Net margin: –65.31 %
- Debt‑to‑equity: 192.9 % (capital‑structure reliance on borrowings).
Free cash flow remains negative (‑$2.7 M in 2021 to ‑$9.1 M in 2025), but the Q2 2026 call disclosed a narrowed quarterly cash burn of $1.8 million after cost‑containment actions.
Historical Profitability Metrics
- ROA: –60.08 % (most recent).
- ROE: –327.1 % (2025).
- EPS: –$2.01 (2025 full year).
These figures underscore an investment‑phase business where revenue growth outweighs immediate earnings.
Comparative Landscape
QT Imaging competes with established breast‑imaging players such as Hologic, GE Healthcare, and Siemens Healthineers. Its acoustic‑CT platform delivers high‑resolution, three‑dimensional images without ionizing radiation, positioning it as a potentially lower‑cost alternative to MRI. Analysts project the global breast‑cancer screening market to exceed $10 billion by 2028, growing at ~6 % CAGR, leaving room for niche technologies that address cost and radiation concerns.
LOPJLB Signal Read
The LOPJLB scanner currently assigns a BUY directional signal to QT Imaging, supported by a Score of 5, the highest tier in the system. The signal is generated within a RECOVERY market regime, indicating that broader equity conditions have shifted from a prior downtrend toward a more supportive environment for risk‑on assets. Composite PERF is –6.10, reflecting recent price volatility, while the FUND quality metric sits at 1.40, modestly above the baseline.
The Value/Growth/GARP/Quality breakdown reads V = 4.00, G = 20.00, GARP = 0.00, Q = 1.40, classifying the stock under the Balanced archetype. In practice, this suggests that the model sees a blend of growth potential (driven by expanding sales and regulatory milestones) tempered by the company’s current valuation and quality constraints (negative earnings, high leverage).
Investors interested in the full overlay—including technical filters and the interactive chart—are encouraged to explore the interactive chart above on the QT Imaging stock page. Detailed methodology behind the signal generation is available at the LOPJLB methodology hub.
Closing Thoughts and Next Steps
QT Imaging’s recent operational highlights—accelerated Q2 shipments, strategic hires to drive U.S. adoption, and clean regulatory approvals in both Israel and the United States—provide tangible catalysts that align with the BUY signal generated by LOPJLB. While the balance sheet remains leveraged and profitability is still a work in progress, the company’s revenue trajectory and expanding commercial footprint suggest a potential inflection point as it transitions from a development‑centric to a revenue‑centric business model.
For a deeper dive into price action, valuation overlays, and the full set of quantitative metrics, visit the dedicated QT Imaging page at lopjlb.com/stock/QTI. The detailed Q2 2026 earnings‑call transcript is available at lopjlb.com/stock/QTI/earnings.md. To explore additional opportunities that meet similar signal criteria, the LOPJLB screener is available at lopjlb.com/screener.
All content herein is for informational purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consult professional advisors before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.